Clinical review: Balancing the therapeutic, safety, and economic issues underlying effective antipseudomonal carbapenem use

Table 2 Probability of meropenem and imipenem attaining pharmacodynamic targets over entire dosing interval for 30, 50, and 100 percent T>MIC for selected bacterial populations [42]

			Pharmacodynamic target for entire dosing interval
	30 percent T > MIC		50 percent T > MIC		100 percent T > MIC
Species	Meropenem	Imipenem	Meropenem	Imipenem	Meropenem	Imipenem
Escherichia coli	100	100	100	100	100	94
Klebsiella pneumoniae	100	100	99	100	99	91
Enterobacter cloacae	100	100	100	100	95	71
Serratia marcescens	99	99	99	99	97	57
Acinetobacter baumannii	83	89	79	88	31	60
Pseudomonas aeruginosa	93	92	87	87	47	27

ISSN: 1364-8535